Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jingqianshu granule for premenstrual syndrome
ChiCTR2200058599Phase 4Not yet recruiting
- Sponsor
- Hebei University of Chinese Medicine
- Start
- Feb 2022
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Jingqianshu in premenstrual syndrome (PMS) (2 arms), sponsored by Hebei University of Chinese Medicine. Primary endpoint: Change in DRSP score after 3 menstrual cycles. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
Jingqianshu
03
Conditions
premenstrual syndrome (PMS)
Beyond the preview
Go deeper on ChiCTR2200058599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058599.